All In Biotech

Drug Trial Radar · NCT07554131

Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
University of OklahomaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fera Pharmaceuticals, LLC
First posted
Apr 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to see if a medicine called echothiophate iodide (Phospholine Iodide) can help treat children with refractory amblyopia. Amblyopia (also called lazy eye) is when one eye doesn't see as well as it should because the brain isn't using that eye correctly. Refractory amblyopia means a lazy eye that's very difficult to treat and it doesn't improve even after using common treatments, such as putting atropine eye drops in the stronger eye to encourage use of the weaker eye. The main questions this study aims to answer are: * Can adding echothiophate iodide eye drops help children who stopped improving with atropine alone start making progress again? * Does using atropine and echothiophate iodide eye drops together work better for older children and adolescents who typically do not respond well to atropine alone? * Besides improving eyesight, can echothiophate iodide eye drops also help with things like depth perception, seeing in crowded spaces, or noticing motion Participants will be asked to: * Participate in the study for a total of 14 weeks * Attend four clinic visits * Use atropine drops in the stronger eye nightly for a total 12 weeks * Use of echothiophate iodide eye drops in the weaker eye in addition to atropine use in the stronger eye, if vision does not improve after 4 weeks of use of atropine alone in the stronger eye * Upload weekly photos of the eyes * Have a slit lamp exam performed at each visit * Have Best Corrected Visual Acuity (BCVA) eye measurements taken at each visit. * Have Optical Coherence Tomography Angiography (OCTA) images taken at at each visit.

Conditions

  • Refractory Amblyopia

Interventions

  • Echothiophate Iodide 0.125% Ophthalmic SolutionDrug

    Participants will receive echothiophate iodide eye drops in addition to standard atropine therapy to assess whether the combination improves visual function in refractory amblyopia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Corrected Visual Acuity (BCVA)Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dean McGee Eye Institute

    Oklahoma City, Oklahoma

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.